BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Immunology - Pharmacology - Rheumatology

CD6 and Syntaxin Binding Protein 6 Variants and Response to Tumor Necrosis Factor Alpha Inhibitors in Danish Patients with Rheumatoid Arthritis
Published: Thursday, June 07, 2012
Author: Sophine B. Krintel et al.

by Sophine B. Krintel, Laurent Essioux, Assaf Wool, Julia S. Johansen, Ehud Schreiber, Tomer Zekharya, Pinchas Akiva, Mikkel Østergaard, Merete L. Hetland


TNFa inhibitor therapy has greatly improved the treatment of patients with rheumatoid arthritis, however at least 30% do not respond. We aimed to investigate insertions and deletions (INDELS) associated with response to TNFa inhibitors in patients with rheumatoid arthritis (RA).

Methodology and Principal Findings

In the DANBIO Registry we identified 237 TNFa inhibitor naïve patients with RA (81% women; median age 56 years; disease duration 6 years) who initiated treatment with infliximab (n?=?160), adalimumab (n?=?56) or etanercept (n?=?21) between 1999 and 2008 according to national treatment guidelines. Clinical response was assessed at week 26 using EULAR response criteria. Based on literature, we selected 213 INDELS potentially related to RA and treatment response using the GeneVa® (Compugen) in silico database of 350,000 genetic variations in the human genome. Genomic segments were amplified by polymerase chain reaction (PCR), and genotyped by Sanger sequencing or fragment analysis. We tested the association between genotypes and EULAR good response versus no response, and EULAR good response versus moderate/no response using Fisher’s exact test. At baseline the median DAS28 was 5.1. At week 26, 68 (29%) patients were EULAR good responders, while 81 (34%) and 88 (37%) patients were moderate and non-responders, respectively. A 19 base pair insertion within the CD6 gene was associated with EULAR good response vs. no response (OR?=?4.43, 95% CI: 1.99–10.09, p?=?7.211×10-5) and with EULAR good response vs. moderate/no response (OR?=?4.54, 95% CI: 2.29–8.99, p?=?3.336×10-6). A microsatellite within the syntaxin binding protein 6 (STXBP6) was associated with EULAR good response vs. no response (OR?=?4.01, 95% CI: 1.92–8.49, p?=?5.067×10-5).


Genetic variations within CD6 and STXBP6 may influence response to TNFa inhibitors in patients with RA.